Rangwala Reshma 4

What Happened

• Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics (KPTI), had 947 performance-based restricted stock units (PSUs) earn and vest on May 13, 2026 (acquired at $0.00).
• On May 14, 2026 she sold 408 shares in a broker-assisted transaction at $9.50 per share, generating $3,876. The sale was to satisfy withholding tax from the PSU vesting and was not a discretionary trade.

Key Details

• Transaction dates/prices: 947 PSUs vested on 2026-05-13 (acquired $0.00); 408 shares sold on 2026-05-14 at $9.50/share (total $3,876).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — PSUs were earned based on completion of enrollment in the Company’s Phase 3 XPORT-EC-042 trial and certified by the Compensation Committee; F2 — sale was effected under a durable automatic sale instruction plan (adopted Apr 4, 2022) to cover tax withholding, broker-assisted and non-discretionary.
• Filing timeliness: Form 4 filed May 15, 2026, which appears to be timely relative to the May 13–14 transactions.

Context

• These were earned performance awards vesting on a clinical milestone (not a market purchase). The subsequent small-value sale (~$3.9K) was routine tax-withholding, not an independent market-timed sale.
• For retail investors, awards that vest on milestones signal compensation tied to operational goals; the small tax-driven sale does not, by itself, indicate management’s market view.